

CASE 4:20921B/C1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 0415864494S</u> Express Mail Label Number	<u>4-26-02</u> Date of Deposit

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
WAGNER ET AL.

Art Unit: 1614

Examiner: Di Nola Baron, L.

APPLICATION NO: 09/920,159

FILED: AUGUST 1, 2001

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents
Washington, D.C. 20231

FEE LETTER


Sir:

Enclosed herewith is a Terminal Disclaimer in the above-identified application.

The Commissioner is hereby authorized to charge the \$110 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis Corporation. An additional copy of this paper is here enclosed.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807



Diane Tso
Attorney for Applicants
Reg. No. 46,012

Date: April 26, 2002